Table 2.

Comparative demographics according to tumoral expression of IL8

	Study population (n = 32)	High IL8 group (n = 8)	Low IL8 group (n = 24)	p-value
Age (years)	62.4 (± 10.1)	61.4 (± 12.6)	62.8 (± 9.4)	0.75
BMI	23.7 (± 3.9)	24.4 (± 4.5)	23.7 (± 3.9)	0.68
CA 125 (U/ml) at baseline	1878.5 (± 2402.6)	3615.6 (± 4010.7)	1299.6 (± 1218.2)	0.01*
Histological type
Serous	81.3% (n = 26)	87.5% (n = 7)	79.2% (n = 19)	0.67
Mucinous	3.1% (n = 1)	0	4.2% (n = 1)
Endometrioid	6.2% (n = 2)	0	8.3% (n = 2)
Undifferentiated	9.4% (n = 3)	12.5% (n = 1)	8.3% (n = 2)
FIGO stage
IIIC	87.5% (n = 28)	75.0% (n = 6)	91.7% (n = 22)	0.08
IV	12.5% (n = 4)	25.0% (n = 2)	8.3% (n = 2)
Number of NAC courses	4 (3–7)	4 (3–6)	4 (3–7)	0.32
Total number of chemotherapy courses	6 (3–12)	6 (3–10)	6 (3–12)	0.24
Delay between diagnosis and surgery (months)	3.7 (2.6–9.3)	3.8 (2.9–7.0)	3.7 (2.6–9.3)	0.42
Completeness of cytoreduction scorea
CC-0	78.1% (n = 25)	62.5% (n = 5)	83.3% (n = 20)	0.22
CC-1	3.1% (n = 1)	0	4.2% (n = 1)
CC-2	12.5% (n = 4)	25.0% (n = 2)	8.3% (n = 2)
CC-3	6.3% (n = 2)	12.5% (n = 1)	4.2% (n = 1)
Duration of surgical procedure (min)	389 (± 127)	360 (± 132)	401 (± 127)	0.52
Disease free survival (months)	29.4 (± 5.1)	12.2 (± 1.0)	35.6 (± 6.5)	0.001**
Overall survival (months)	54.8 (± 6.1)	32.4 (± 7.3)	63.3 (± 7.1)	0.009**
Chemoresistance
Yes	57.2% (n = 16)	100.0% (n = 8)	40.0% (n = 8)	0.004**
No	42.8% (n = 12)	0	60.0% (n = 12)

BMI body mass index, NAC neoadjuvant chemotherapy

^aA CC-0 score indicates a complete disease removal; a CC-1 score indicates that tumor nodules persisting after cytoreduction were < 2.5 mm in diameter; a CC-2 score indicates residual tumor nodules between 2.5 mm and 25 mm in diameter; a CC-3 score indicates residual tumor nodules > 25 mm in diameter or a confluence of unresectable tumor nodules at any site within the abdomen or pelvis